Chicago Atlantic BDC LIEN 深 滬
等待開盤 07-24 09:30:00 美东时间
10.40
-0.230
-2.16%
華盛通- 最 高10.55
- 今 開10.51
- 成交量 2.01万股
- 最 低 10.374
- 昨 收 10.63
- 總市值 2.37亿
- 52周最高 12.36
- 市盈率 靜 11.18
- 換手率 0.09%
- 52周最低 9.36
- 委 比 -65.53%
- 總股本 2282.04万
- 歷史最高 12.36
- 量 比 0.76
- 振 幅 1.66%
- 歷史最低 4.42
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Chicago Atlantic BDC, Inc. Announces Second Quarter 2025 Financial Results Conference Call
Chicago Atlantic BDC, a specialty finance company regulated as a business development company, announced the release of its second quarter 2025 financial results on August 14, 2025. The results were made public before the market opened, followed by a live audio webcast and conference call at 9:00 a.m. ET. Participants can dial (833) 630-1956 (or 412-317-1837 for international callers) and access the webcast at lien.chicagoatlantic.com. A replay o...
今天 11:00
Chicago Atlantic BDC Appoints New Interim CFO
Chicago Atlantic BDC ( ($LIEN) ) just unveiled an update. On July 1, 2025, Mart...
07-03 19:51
Chicago Atlantic BDC, Inc. Announces 2025 Annual Meeting of Stockholders’ Date
Chicago Atlantic BDC, Inc. ("LIEN") announced its 2025 Annual Meeting of Stockholders will be held on June 25, 2025, at 10:00 AM ET, conducted virtually. Stockholders of record as of April 25, 2025, can attend via www.virtualshareholdermeeting.com/LIEN2025. The meeting agenda includes re-electing Supurna VedBrat to the Board until 2028 and ratifying BDO USA as the independent auditor for 2025. Stockholders are encouraged to vote by visiting www.p...
06-03 11:00
Reported Sunday, Taiho And Cullinan's Zipalertinib Shows 40% ORR In Platinum-Treated EGFR ex20ins NSCLC, REZILIENT1 Results Published In JCO
Highlights of the REZILIENT1 Phase 1/2 trial in the authors' conclusions include:Zipalertinib demonstrated clinically meaningful efficacy in the primary efficacy population (n=176), including 51 patients who had received
06-02 15:31
Cullinan Therapeutics And Taiho To Present Phase 2b Results From REZILIENT1 Trial Of Zipalertinib In Previously Treated EGFR ex20ins NSCLC At ASCO 2025
Cullinan Therapeutics, Inc. (NASDAQ:CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2
05-23 05:33
Chicago Atlantic BDC Reports Strong Q1 2025 Earnings
Silver Spike Investment Corp. ( ($LIEN) ) has released its Q1 earnings. Here is...
05-15 11:55
Chicago Atlantic BDC declares $0.34 dividend
Chicago Atlantic BDC (NASDAQ:LIEN) declares $0.34/share quarterly dividend, in line with previous. Forward yield 13.77% Payable July 11; for shareholders of record June 27; ex-div June 27. See LIEN Di...
05-14 20:50
Chicago Atlantic BDC Q1 EPS $0.34, Inline
Chicago Atlantic BDC (NASDAQ:LIEN) reported quarterly earnings of $0.34 per share which met the analyst consensus estimate. This is a 3500 percent increase over losses of $(0.01) per share from the same period last year.
05-14 19:02
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
Cullinan Therapeutics Receives EMA Approval For CLN-978; Phase 1 Study In Active, Difficult-To-Treat Rheumatoid Arthritis To Initiate In Q2 2025
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025CLN-978 expands into Sjögren's disease; Phase 1 study in
05-08 19:07
